Recently, growing reports have indicated that DLX6-AS1 could interact with the target miRNAs to regulate the progression and treatment resistance of multiple cancers, including lung adenocarcinoma (LUAC)12, ovarian cancer13, hepatocellular cancer (HCC)14, glioma15 and bladder cancer16. Here, DLX6 is linked to cancer.